**Candel Therapeutics Reports Financial Results and Operational Progress in 10-K Filing**

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company, has released its 10-K filing, detailing its financial performance and operational activities. The company, focused on developing off-the-shelf viral immunotherapies for cancer treatment, reported no revenue for the fiscal years 2025 and 2024, consistent with its status as a pre-commercial entity. The net loss for 2025 was $38.2 million, a decrease from the $55.2 million loss reported in 2024. This decrease in net loss was primarily attributed to an $8.2 million decrease in the fair value of warrant liabilities, compared to a $20.8 million increase in 2024.

Operating expenses for 2025 totaled $48.3 million, compared to $33.4 million in 2024. Research and development expenses increased to $30.5 million in 2025 from $19.3 million in 2024, driven by increased clinical development costs for aglatimagene programs. General and administrative expenses also rose to $17.8 million in 2025 from $14.1 million in 2024, reflecting increased commercial readiness costs and employee-related expenses. The company's cash and cash equivalents stood at $119.7 million as of December 31, 2025.

Operationally, Candel Therapeutics highlighted the progress of its lead product candidate, aglatimagene, including positive topline data from its Phase 3 clinical trial in localized prostate cancer. The company is preparing for a Biologics License Application (BLA) submission to the FDA in the fourth quarter of 2026. Additionally, a pivotal Phase 3 clinical trial of aglatimagene in non-small cell lung cancer (NSCLC) is planned for the second quarter of 2026. The company also reported progress with linoserpaturev, its HSV-based product candidate, currently in an investigator-sponsored Phase 1b clinical trial for recurrent high-grade glioma (HGG).

In February 2026, Candel entered into a purchase and sale agreement with RTW Investments, LP, securing $100 million upon FDA approval of aglatimagene for localized prostate cancer, in exchange for a tiered royalty on future net sales in the United States. The company also completed a follow-on offering in February 2026, raising approximately $93.5 million in net proceeds. Candel Therapeutics anticipates that its existing cash and cash equivalents, combined with the proceeds from the February 2026 offering, will be sufficient to fund operations into the first quarter of 2028. The company's workforce comprised 55 employees as of December 31, 2025, with 44 dedicated to research and development.

About Candel Therapeutics, Inc.

Candel Therapeutics develops off-the-shelf viral immunotherapies targeting solid tumors. Its platforms utilize genetically engineered adenoviruses and herpes simplex viruses to induce tumor cell death and stimulate systemic anti-tumor immune responses. Key products, including CAN-2409 and CAN-3110, aim to treat cancers like prostate, lung, pancreatic, and glioma by converting "cold" tumors into "hot," enhancing immune recognition, with a focus on combination therapies and regulatory approval pathways.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.